Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3)

Cell Biochemistry and Function

Volumn 29, Issue 2, 2011, Pages 87-95

  Senthilkumar, Kalimuthu ^a   Arunkumar, Ramachandran ^a   Elumalai, Perumal ^a   Sharmila, Govindaraj ^a   Gunadharini, Dharmalingam Nandhagopal ^a   Banudevi, Sivanantham ^a   Krishnamoorthy, Gunasekar ^a   Benson, Chellakan Selvanesan ^a   Arunakaran, Jagadeesan ^a  

^a Dr ALMPGIBMS: Endocrinology   (India)

Author keywords

catenin; C.Fos; C.Jun; EGF R; Nuclear factor kappa B; Quercetin; Urokinase plasminogen activator

Indexed keywords

BETA CATENIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN C JUN; QUERCETIN; RAF PROTEIN; UROKINASE;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; DOWN REGULATION; HUMAN; HUMAN CELL; IC 50; MALE; NUCLEOTIDE SEQUENCE; ONCOGENE C FOS; ONCOGENE N RAS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; QUERCETIN; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SIGNAL TRANSDUCTION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 79952211178     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1725     Document Type: Article

References (46)

1. David L, Seruca R, Nesland JM, Soares P, Sansonetty F, Holm R, Borresen AL, Sobrinho-Simoes M. c-erbB-2 expression in primary gastric carcinomas and their metastases. Mod Pathol 1992; 5: 384-390.
2. Scher HI, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Fuks Z, Mendelsohn J, Cordon-Cardo C. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res 1995; 1: 545-550.
3. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Hittmair A, Zhang J. Regulation of prostatic growth and function by peptide growth factors. Prostate 1996; 28: 392-405.
4. Culig Z, Hobisch A, Bartsch G, Klocker H. Androgen receptor - an update of mechanisms of action in prostate cancer. Urol Res 2000; 28: 211-219.
5. Vassalli JD, Pepper MS. Tumour biology. Membrane proteases in focus. Nature 1994; 370: 14-15.
6. Yebra M, Parry GC, Strömblad S, Mackman N, Rosenberg S, Mueller BM, Cheresh DA. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alpha v beta 5-directed cell migration. J Biol Chem 1996; 271: 29393-29399.
7. Nguyen DH, Hussaini IM, Gonias SL. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem 1998; 273: 8502-8507.
8. Aguirre Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999; 147: 89-104.
9. Pakneshan P, Xing RH, Rabbani SA. Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo. FASEB J 2003; 17: 1081-1088.
10. Weber JD, Hu W, Jefcoat SC, Jr., Raben DM, Baldassare JJ. Ras-stimulated extracellular signal-related kinase 1 and RhoA activities coordinate platelet-derived growth factor-induced G1 progression through the independent regulation of cyclin D1 and p27. J Biol Chem 1997; 272: 32966-32971.
11. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002; 8: 3438-3444.
12. Thanos D, Maniatis T. NF-B: a lesson in family values. Cell 1995; 80: 529-532.
13. Muller CW, Rey FA, Sodeoka M, Verdine GL, Harrison SC. Structure of the NF-kB p50 homodimer bound to DNA. Nature 1995; 373: 311-317.
14. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999; 2: 82-85.
15. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, Da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509-1512.
16. Aviram M, Fuhrman B. Wine flavonoids protect against LDL oxidation and atherosclerosis. Ann NY Acad Sci 2002; 957: 146-161.
17. Choi JA, Kim JY, Lee JY, Kang CM, Kwon HJ, Yoo YD, Kim TW, Lee YS, Lee SJ. Induction of cell cycle arrest and apoptosis in human breast cancer cells by quercetin. Int J Oncol 2001; 19: 837-844.
18. Kuo PC, Liu HF, Chao JI. Survivin and p53 modulate quercetin-induced cell growth inhibition and apoptosis in human lung carcinoma cells. J Biol Chem 2004; 279: 55875-55885.
19. Ong CS, Tran E, Nguyen TT, Ong CK, Lee SK, Lee JJ, Ng CP, Leong C, Huynh H. Quercetin-induced growth inhibition and cell death in nasopharyngeal carcinoma cells are associated with increase in Bad and hypophosphorylated retinoblastoma expressions. Oncol Rep 2004; 11: 727-733.
20. Vijayababu MR, Kanagaraj P, Arunkumar A, Ilangovan R, Dharmarajan A, Arunakaran J. Quercetin induces p53-independent apoptosis in human prostate cancer cells by modulating Bcl-2-related proteins: a possible mediation by IGFBP-3. Oncol Res 2006; 16; 67-74.
21. Choi EJ, Bae SM, Ahn WS. Antiproliferative effects of quercetin through cell cycle arrest and apoptosis in human breast cancer MDA-MB-453 cells. Arch Pharm Res 2009; 31: 1281-1285.
22. Jung YH, Heo J, Lee JY, Kwon KT, Kim HK. Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5. Life Sci 2010; 86: 351-357.
23. Nair HK, Rao KV, Aalinkeel R, Mahajan S, Chawda R, Schwartz SA. Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol 2004; 11: 63-69.
24. Chowdhury SA, Kishino K, Satoh R, Hashimoto K, Kikuchi H, Nishikawa H, Shirataki Y, Sakagami H. Tumor-specificity and apoptosis-inducing activity of stilbenes and flavonoids. Anticancer Res 2005; 25: 2055-2063.
25. Luttrell LM, Daaka Y, Della Rocca GJ, Lefkowitz RJ. G protein-coupled receptors mediate two functionally distinct pathways of tyrosine phosphorylation in rat 1a fibroblasts. Shc phosphorylation and receptor endocytosis correlate with activation of Erk kinases. J Biol Chem 1997; 272: 31648-31656.
26. Kloth MT, Laughlin KK, Biscardi JS, Boerner JL, Parsons SJ, Silva CM. STAT5b, a mediator of synergism between c-Src and the epidermal growth factor receptor. J Biol Chem 2003; 278: 1671-1679.
27. Jo M, Thomas KS, Wu L, Gonias SL. Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling. J Biol Chem 2003; 278: 46692-46698.
28. Jo M, Thomas SK, Marozkina N, Amin TJ, Silva CM, Parsons SJ, Gonias SL. Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator. J Biol Chem 2005; 280: 17449-17457.
29. Dunn ES, Torres JV, Oh SJ, Cykert MD, Carl Barrett J. Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. Cancer Res 2002; 61: 1367-1374.
30. Vijayababu MR, Arunkumar A, Kanagaraj P, Ilangovan R, Aruldhas MM, Arunakaran J. Quercetin- induced growth inhibition and cell death in prostate carcinoma cells (PC-3) are associated with increase in p21 and hypophosporylated retinoblastoma proteins expression. J Cancer Res Clin Oncol 2005; 131: 765-771.
31. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999; 402: 884-888.
32. Ma Z, Webb DJ, Jo M, Gonias SL. Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J Cell Sci 2001; 114: 3387-3396.
33. Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet 2001; 10: 699-703.
34. Curran T, Vogt PK. Dangerous liaisons: Fos and Jun, oncogenic transcription factors. In Transcriptional Regulation. McKnight SL, Yamamoto KR (eds.). Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1992; 797-831.
35. Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, Golub T, Mellinghoff IK, Davis RJ, Wu H, Sawyers CL. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell 2007; 11: 555-569.
36. Agarwal SK, Novotny EA, Crabtree JS, Weitzman JB, Yaniv M, Burns AL, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ. Transcription factor JunD, deprived of menin, switches from growth suppressor to growth promoter. Proc Natl Acad Sci 2003; 16: 10770-10775.
37. Kim GY, Mercer SE, Ewton DZ, Yan Z, Jin K, Friedman E. The stress-activated protein kinases p38 alpha and JNK1 stabilize p21(Cip1) by phosphorylation. J Biol Chem 2002; 277: 29792-29802.
38. Lavoie JN, L'Allemain G, Brunet A, Müller R, Pouysségur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 2006; 271: 20608-206016.
39. Yee AS, Paulson EK, McDevitt MA, Rieger-Christ K, Summerhayes I, Berasi SP, Kim J, Huang CY, Zhang X. The HBP1 transcriptional repressor and the p38 MAP kinase: unlikely partners in G1 regulation and tumor suppression. Gene 2004; 336: 1-13.
40. Casanovas O, Miró F, Estanyol MJ, Itarte E, Agell N, Bachs O. Osmotic stress regulates the stability of cyclin D1 in a p38SAPK2-dependent manner. J Biol Chem 2000; 275: 35091-35097.
41. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998; 281: 1680-1683.
42. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999; 401: 86-90.
43. Liu D, Aguirre Ghiso J, Estrada Y, Ossowski L., EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 2002; 1: 445-457.
44. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003; 116: 1175-1186.
45. Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem 1998; 273: 19929-19932.
46. Senthilkumar K, Elumalai P, Arunkumar R, Banudevi S, Gunadharini ND, Sharmila G, Selvakumar K, Arunakaran J. Quercetin regulates insulin like growth factor signaling and induces intrinsic and extrinsic pathway mediated apoptosis in androgen independent prostate cancer cells (PC-3). Mol Cell Biochem 2010; 344: 173-184.